Korean Biotechs Rush To Rights Offerings To Raise R&D Funds
Large VC Financing Still Limited
Executive Summary
Listed Korean bioventures are increasingly opting for rights offerings in a high interest rate environment, while unlisted firms are turning more to smaller-scale VC financings.